Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis

被引:166
作者
Chawla, Lakhmir S.
Seneff, Michael G.
Nelson, David R.
Williams, Mark
Levy, Howard
Kimmel, Paul L.
Macias, William L.
机构
[1] George Washington Univ, Med Ctr, Dept Anesthesiol & Crit Care Med, Washington, DC 20037 USA
[2] George Washington Univ, Med Ctr, Dept Med, Div Renal Dis & Hypertens, Washington, DC 20037 USA
[3] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2007年 / 2卷 / 01期
关键词
D O I
10.2215/CJN.02510706
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Acute kidney injury (AKI) is common in critically ill patients with severe sepsis (SS), and the predictors of AKI in this population have not been well characterized. The study group was the placebo group of the Prospective Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) data set. PROWESS is a prospective, randomized, controlled study of the use of drotrecogin a (activated) for the treatment of SS. Placebo patients who had an admission renal sepsis organ failure score of 2 or more were excluded. AKI was defined as an increase in serum creatinine of 25% or 0.3 mg/dl during the first week postbaseline. The incidence of relevant parameters was then compared in patients with and without AKI. Half of the patients were randomly assigned to a model-building data set, and multivariable Cox regression was used to determine risk factors. Factors that remained significant in the remaining "model validation" data set were considered significant. Of the 840 patients in the placebo group, 547 met inclusion criteria. Of the 547 patients, 127 (23.2%) patients met criteria for AKI. The mean age of the 547 patients was 59.8 +/- 17.0, and 43.3% of the cohort were female. The ethnicity breakdown was as follows: White 83.2%, black 5.9%, and other 11%. Univariate analyses indicated that patients with AKI had a higher incidence of a dependence on the basis of activity of daily living scale (38.6 versus 26.7%; P=0.01), a lower baseline platelet count (193,000 versus 222,000; P=0.02), a higher baseline respiratory Sepsis Organ Failure Assessment score (2.9 versus 2.7; P=0.02), higher preinfusion Acute Physiology and Chronic Health Evaluation II (APACHE II) score (24.8 versus 22.0; P=0.0002), older age (63.7 versus 58.7 yr; P=0.008), and higher log IL-6 (6.6 versus 5.8; P=0.0006). In a multivariable Cox regression, the predictors of AKI were log IL-6 (P<0.0001) and APACHE II (P=0.0008). Increased log IL-6 and APACHE II score are significant risk factors of AKI in patients with SS. IL-6 data and the absence of correlation with measures of hypotension (e.g., mean arterial pressure, dosage of vasopressors) support the notion that inflammation is a significant component of AKI in SS.
引用
收藏
页码:22 / 30
页数:9
相关论文
共 41 条
[1]
Abraham E, 1998, LANCET, V351, P929
[2]
Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients [J].
Abraham, E ;
Laterre, PF ;
Garbino, J ;
Pingleton, S ;
Butler, T ;
Dugernier, T ;
Margolis, B ;
Kudsk, K ;
Zimmerli, W ;
Anderson, P ;
Reynaert, M ;
Lew, D ;
Lesslauer, W ;
Passe, S ;
Cooper, P ;
Burdeska, A ;
Modi, M ;
Leighton, A ;
Salgo, M ;
Van der Auwera, P .
CRITICAL CARE MEDICINE, 2001, 29 (03) :503-510
[3]
Anaritide in acute tubular necrosis [J].
Allgren, RL ;
Marbury, TC ;
Rahman, SN ;
Weisberg, LS ;
Fenves, AZ ;
Lafayette, RA ;
Sweet, RM ;
Genter, FC ;
Kurnik, BRC ;
Conger, JD ;
Sayegh, MH .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (12) :828-834
[4]
American Society of Nephrology, 2005, J Am Soc Nephrol, V16, P1886
[5]
Bellomo R, 2000, LANCET, V356, P2139
[6]
Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[7]
DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[8]
Acute renal failure in intensive care units - Causes, outcome, and prognostic factors of hospital mortality: A prospective, multicenter study [J].
Brivet, FG ;
Kleinknecht, DJ ;
Loirat, P ;
Landais, PJM ;
Bedock, B ;
Bleichner, G ;
Richard, C ;
Coste, F ;
BrunBuisson, C ;
Sicot, C ;
Tenaillon, A ;
Gajdos, P ;
Blin, F ;
Saulnier, F ;
Agostini, MM ;
Nicolas, F ;
FeryLemonnier, E ;
Staikowski, F ;
Carlet, J ;
Guivarch, G ;
Fraisse, F ;
Ricome, J ;
Tempe, JD ;
Mezzarobba, P .
CRITICAL CARE MEDICINE, 1996, 24 (02) :192-198
[9]
Identifying critically ill patients at high risk for developing acute renal failure: A pilot study [J].
Chawla, LS ;
Abell, L ;
Mazhari, R ;
Egan, M ;
Kadambi, N ;
Burke, HB ;
Junker, C ;
Seneff, MG ;
Kimmel, PL .
KIDNEY INTERNATIONAL, 2005, 68 (05) :2274-2280
[10]
Outcomes and APACHE II predictions for critically ill patients with acute renal failure requiring dialysis [J].
Chen, YC ;
Hsu, HH ;
Kao, KC ;
Fang, JT ;
Huang, CC .
RENAL FAILURE, 2001, 23 (01) :61-70